Teva gets blowout number two in Swiss francs
Teva Pharmaceutical Industries, the Israeli generic drug company, hit the Swiss franc jackpot on Monday with an oversubscribed Sfr450m issue, its debut in the currency.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts